Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing
Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing
复制标题
DOI：
10.1126/science.287.5459.1816
复制
发表时间：
2000-03-10
期刊：
影响因子：
56.9
通讯作者：
Rappuoli, R
中科院分区：
文献类型：
--
作者：
Pizza, M;Scarlato, V;Rappuoli, R
脑膜炎奈瑟菌是细菌性败血症和脑膜炎的主要原因。表面暴露蛋白的序列变异和血清群B荚膜多糖与人体组织的交叉反应性阻碍了开发成功疫苗的努力。为了克服这些障碍，使用强毒血清群B菌株（MC 58）的全基因组序列来鉴定疫苗候选物。共表达了350个候选抗原，并进行了纯化。并用于免疫小鼠。血清允许鉴定表面暴露的蛋白质，这些蛋白质在一系列菌株中序列保守，并且诱导杀菌抗体应答，这是一种已知与人类疫苗功效相关的特性。
Neisseria meningitidis is a major cause of bacterial septicemia and meningitis. Sequence variation of surface-exposed proteins and cross-reactivity of the serogroup B capsular polysaccharide with human tissues have hampered efforts to develop a successful vaccine. To overcome these obstacles, the entire genome sequence bf a virulent serogroup B strain (MC58) was used to identify vaccine candidates. A total of 350 candidate antigens were expressed in Escherichia coli, purified. and used to immunize mice. The sera allowed the identification of proteins that are surface exposed, that are conserved in sequence across a range of strains, and that induce a bactericidal antibody response, a property known to correlate with vaccine efficacy in humans.